GREY:IMVIF - Post by User
Post by
Breakthoroughon Nov 12, 2020 12:32pm
895 Views
Post# 31885634
The pembro trial may be...
The pembro trial may be...https://www.clinicaltrials.gov/ct2/show/NCT03990961?term=Pembrolizumab&cond=DLBCL&draw=2&rank=1 Or this: "The overall and complete response rate was 90% and 77%. With 255 months of median follow-up, 2-year progression-free survival (PFS) is 83%. PD-L1 expression was associated with non-GCB subtype, and improved PFS and survival. Pembrolizumab can safely be added to R-CHOP, and is associated with a high CR rate and 2-year PFS." https://pubmed.ncbi.nlm.nih.gov/32030732/